Bastiano Sanna, EVP, Cell & Genetic Therapies at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 45 shares at $250.56 ($11K) on 2022-05-16, disclosed to the SEC on 2022-05-18.
Scheduled sale ($11k) by EVP, Cell & Genetic Therapies under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $250.56 | 7 | $2K | 15.4% |
| 2 | $251.37 | 8 | $2K | 17.7% |
| 3 | $252.43 | 7 | $2K | 15.5% |
| 4 | $253.99 | 15 | $4K | 33.5% |
| 5 | $254.44 | 8 | $2K | 17.9% |
| Total | $252.83 avg | 45 |
| $11K |
| 100% |
| Filing → |
| VRTX | SELL | 2023-04-14 | $4.9M | — | Filing → |
| VRTX | SELL | 2023-04-06 | $231K | — | Filing → |
| VRTX | SELL | 2023-03-20 | $1.7M | — | Filing → |